ERBB2 and neoplasm: The overall discordance of HER2 gene amplification including patients with HER2+ primary tumor with HER2− CTCs and DTCs and HER2− primary tumor with HER2+ CTCs and DTCs amounted to 15% for CTCs and 28.2% for DTCs.